Captrust Financial Advisors Sells 2,592 Shares of HCA Healthcare, Inc. (NYSE:HCA)

Captrust Financial Advisors lessened its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 0.8% in the third quarter, Holdings Channel.com reports. The firm owned 303,028 shares of the company’s stock after selling 2,592 shares during the period. Captrust Financial Advisors’ holdings in HCA Healthcare were worth $123,160,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in HCA. Alpha DNA Investment Management LLC bought a new position in shares of HCA Healthcare in the 3rd quarter valued at about $869,000. EP Wealth Advisors LLC grew its holdings in shares of HCA Healthcare by 1.6% in the 2nd quarter. EP Wealth Advisors LLC now owns 225,146 shares of the company’s stock valued at $72,335,000 after acquiring an additional 3,516 shares in the last quarter. AustralianSuper Pty Ltd grew its holdings in shares of HCA Healthcare by 118.5% in the 3rd quarter. AustralianSuper Pty Ltd now owns 35,493 shares of the company’s stock valued at $14,425,000 after acquiring an additional 19,247 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of HCA Healthcare by 3.3% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 162,654 shares of the company’s stock valued at $52,257,000 after acquiring an additional 5,136 shares in the last quarter. Finally, Mizuho Securities USA LLC lifted its stake in HCA Healthcare by 205.4% in the 3rd quarter. Mizuho Securities USA LLC now owns 45,637 shares of the company’s stock valued at $18,548,000 after purchasing an additional 30,693 shares during the last quarter. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

Shares of NYSE:HCA opened at $325.47 on Friday. The company’s 50 day simple moving average is $373.42 and its 200 day simple moving average is $358.28. The stock has a market capitalization of $82.44 billion, a price-to-earnings ratio of 14.61, a price-to-earnings-growth ratio of 1.25 and a beta of 1.68. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00. HCA Healthcare, Inc. has a 1 year low of $245.84 and a 1 year high of $417.14.

HCA Healthcare Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be paid a $0.66 dividend. The ex-dividend date is Friday, December 13th. This represents a $2.64 dividend on an annualized basis and a yield of 0.81%. HCA Healthcare’s dividend payout ratio (DPR) is 11.85%.

Insider Activity at HCA Healthcare

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the sale, the insider now owns 6,843 shares of the company’s stock, valued at approximately $2,415,579. The trade was a 29.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael S. Cuffe sold 8,358 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the sale, the executive vice president now directly owns 29,678 shares in the company, valued at approximately $11,438,494.76. The trade was a 21.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 15,155 shares of company stock valued at $5,608,990 over the last three months. 1.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on HCA shares. UBS Group raised their target price on shares of HCA Healthcare from $405.00 to $438.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. StockNews.com downgraded shares of HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. TD Cowen cut their price objective on shares of HCA Healthcare from $450.00 to $440.00 and set a “buy” rating for the company in a research report on Monday, October 28th. Wells Fargo & Company downgraded shares of HCA Healthcare from an “equal weight” rating to an “underweight” rating and cut their price objective for the stock from $400.00 to $320.00 in a research report on Monday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $392.00 price objective on shares of HCA Healthcare in a research report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $380.29.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.